Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Paclitaxel + Raludotatug deruxtecan |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Paclitaxel | Taxol | 7-Epipaclitaxel | Antimicrotubule Agent 14 BCL2 Family Inhibitor 6 | Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary). |
| Raludotatug deruxtecan | DS 6000a|DS-6000|DS6000a|DS-6000a|R-DXd|MK-5909 | Raludotatug deruxtecan (DS-6000a) is an antibody-drug conjugate (ADC) comprising a monoclonal antibody targeting CDH6 linked to the cytotoxic DNA topoisomerase inhibitor DXd, which binds to CDH6 expressed on tumor cells and potentially induces tumor cell apoptosis and inhibits tumor growth (PMID: 38205802). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06843447 | Phase Ib/II | Pembrolizumab + Raludotatug deruxtecan Carboplatin + Raludotatug deruxtecan Paclitaxel + Raludotatug deruxtecan Bevacizumab + Raludotatug deruxtecan | A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003) | Recruiting | USA | ISR | GBR | ESP | 0 |